- Home
- NTIP vs COEP Comparison
NTIP vs COEP Comparison
Compare NTIP & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- COEP
- Stock Information
- Founded
- NTIP 1990
- COEP 2017
- Country
- NTIP United States
- COEP United States
- Employees
- NTIP N/A
- COEP N/A
- Industry
- NTIP Multi-Sector Companies
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTIP Miscellaneous
- COEP Health Care
- Exchange
- NTIP Nasdaq
- COEP Nasdaq
- Market Cap
- NTIP 32.9M
- COEP 32.4M
- IPO Year
- NTIP 1998
- COEP N/A
- Fundamental
- Price
- NTIP $1.37
- COEP $10.80
- Analyst Decision
- NTIP
- COEP
- Analyst Count
- NTIP 0
- COEP 0
- Target Price
- NTIP N/A
- COEP N/A
- AVG Volume (30 Days)
- NTIP 18.2K
- COEP 59.8K
- Earning Date
- NTIP 02-28-2025
- COEP 05-09-2025
- Dividend Yield
- NTIP 7.35%
- COEP N/A
- EPS Growth
- NTIP N/A
- COEP N/A
- EPS
- NTIP N/A
- COEP N/A
- Revenue
- NTIP $100,000.00
- COEP N/A
- Revenue This Year
- NTIP N/A
- COEP N/A
- Revenue Next Year
- NTIP N/A
- COEP N/A
- P/E Ratio
- NTIP N/A
- COEP N/A
- Revenue Growth
- NTIP N/A
- COEP N/A
- 52 Week Low
- NTIP $1.22
- COEP $2.31
- 52 Week High
- NTIP $2.19
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- NTIP 47.12
- COEP 52.28
- Support Level
- NTIP $1.33
- COEP $10.00
- Resistance Level
- NTIP $1.38
- COEP $11.58
- Average True Range (ATR)
- NTIP 0.03
- COEP 1.33
- MACD
- NTIP -0.00
- COEP -0.14
- Stochastic Oscillator
- NTIP 33.33
- COEP 47.60
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.